Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Fineline Cube May 9, 2026
Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Fineline Cube May 9, 2026
Company Deals

BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda

Fineline Cube Oct 25, 2022

China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has...

Company Deals

Shandong Branden Medical Devices Files for IPO on STAR Board to Raise RMB 760M

Fineline Cube Oct 25, 2022

China-based Shandong Branden Medical Devices Co., Ltd has filed for an initial public offering (IPO)...

Company Deals

Gan & Lee Pharmaceuticals Plans RMB 814M Private Placement for Working Capital

Fineline Cube Oct 25, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced plans to raise up to RMB...

Company Deals

Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D

Fineline Cube Oct 25, 2022

Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of...

Company Drug

Daiichi Sankyo Initiates Global Phase II Study of DS7300 for Small-Cell Lung Cancer

Fineline Cube Oct 25, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced the first patient dosing in a global...

Company Drug

Abbisko’s ABSK021 Gets CDE Approval for Phase III Study in Giant Cell Tumor of Tendon Sheath

Fineline Cube Oct 25, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

Livzon Launches National Rollout of COVID-19 Vaccine V-01 in China

Fineline Cube Oct 25, 2022

China-based Livzon Pharmaceutical Group (HKG: 1513) has announced the national promotion of its recombinant novel...

Company Deals

Venmedtech Raises Series B+ Funding for Iliac Vein Stent and Product R&D

Fineline Cube Oct 25, 2022

Venmedtech, a Suzhou-based one-stop intravenous therapy product platform, has reportedly raised “tens of millions” of...

Company Deals

Celgenyx Completes RMB 100M Series A Financing for Next-Gen Cell Therapy Development

Fineline Cube Oct 25, 2022

China-based Hangzhou Celgenyx Gene Technology Co., Ltd has announced the completion of a Series A...

Company Deals

Easy-Flow Medical Secures Angel Funding for Peripheral Device Development

Fineline Cube Oct 25, 2022

China-based peripheral interventional device manufacturer Shanghai Easy-Flow Medical Tech Co., Ltd has reportedly raised “tens...

Company Drug

Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer

Fineline Cube Oct 24, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a...

Company Deals

Zhejiang Pushkang Biotech Raises RMB 100M in Series C+ Financing

Fineline Cube Oct 24, 2022

China-based Zhejiang Pushkang Biotechnology Co., Ltd, a leading centrifugal microfluidic platform company, has reportedly raised...

Company Deals R&D

Sinovac Partners with Colombia University to Boost Vaccine R&D

Fineline Cube Oct 24, 2022

China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA)...

Company Deals

SeeNeuro Medical Raises RMB 100M in Series B Funding for Neural Regulation Devices

Fineline Cube Oct 24, 2022

Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100...

Company Drug

MicuRx Pharmaceuticals Concludes US Phase I Study for MRX-8

Fineline Cube Oct 24, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I...

Company Drug

Henlius Biotech’s Hanbeitai Approved for Hepatocellular Carcinoma

Fineline Cube Oct 24, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the...

Company Drug

Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications

Fineline Cube Oct 24, 2022

China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...

Company Drug

AIM Vaccine Receives CDE Approval for Serum-Free Rabies Vaccine Trial

Fineline Cube Oct 24, 2022

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...

Company Deals

Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M

Fineline Cube Oct 24, 2022

China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to...

Company

Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline

Fineline Cube Oct 24, 2022

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...

Posts pagination

1 … 608 609 610 … 662

Recent updates

  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
  • CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
  • Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.